pegcetacoplan

Apellis abandons ALS drug after study miss
Apellis abandons ALS drug after study miss
BioPharma Dive
Apellis Pharmaceuticals
ALS
clinical trials
pegcetacoplan
Flag link:
Apellis’ immune system drug hits a setback in ALS
Apellis’ immune system drug hits a setback in ALS
BioPharma Dive
Apellis Pharmaceuticals
clinical trials
ALS
pegcetacoplan
Flag link:
FDA Approves Apellis' Syfovre as First Treatment for Geographic Atrophy
FDA Approves Apellis' Syfovre as First Treatment for Geographic Atrophy
BioSpace
Apellis Pharmaceuticals
Syfovre
pegcetacoplan
FDA
geographic atrophy
Flag link:
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
Investors Business Daily
Apellis Pharmaceuticals
pegcetacoplan
eye disease
geographic atrophy
Flag link:
Apellis Surges By Double Digits As FDA Mulls Its Eye-Disease Treatment
Apellis Surges By Double Digits As FDA Mulls Its Eye-Disease Treatment
Investors Business Daily
Apellis Pharmaceuticals
geographic atrophy
FDA
pegcetacoplan
Flag link:
Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month data
Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month data
Fierce Pharma
Apellis
pegcetacoplan
geographic atrophy
FDA
Flag link:
Apellis' eye med application on track for next year after FDA OKs inclusion of phase 2 data
Apellis' eye med application on track for next year after FDA OKs inclusion of phase 2 data
Fierce Pharma
Apellis Pharmaceuticals
pegcetacoplan
FDA
clinical trials
age-related macular degeneration
Flag link:
Apellis eye drug succeeds in one key study, but falls short in its twin
Apellis eye drug succeeds in one key study, but falls short in its twin
BioPharma Dive
Apellis Pharmaceuticals
FDA
pegcetacoplan
geographic atrophy
Flag link:
Go or no go? Apellis and Heron head for the finish line
Go or no go? Apellis and Heron head for the finish line
EP Vantage
Apellis
anemia
pegcetacoplan
Heron Therapeutics
HTX-011
FDA
Flag link:
Apellis' Soliris rival gets a date at the FDA for a rare blood disorder, with potentially $400M worth of implications
Apellis' Soliris rival gets a date at the FDA for a rare blood disorder, with potentially $400M worth of implications
Endpoints
Apellis
pegcetacoplan
PNH
Flag link:
As CEO bounces back from Covid-19, Apellis says FDA meeting clears path to file for an OK on Soliris rival
As CEO bounces back from Covid-19, Apellis says FDA meeting clears path to file for an OK on Soliris rival
Endpoints
Apellis
FDA
PNH
pegcetacoplan
COVID-19
Flag link:
Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels
Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels
Reuters
Apellis Pharmaceuticals
Alexion Pharmaceuticals
PNH
pegcetacoplan
Soliris
Flag link: